Denosumab Dosing for Hypercalcemia in ESRD Patients

Dosing Regimen

The American College of Cardiology is not mentioned, however, the National Comprehensive Cancer Network recommends denosumab 120 mg subcutaneously for treating hypercalcemia in ESRD patients, particularly in cases of immobilization-related or refractory hypercalcemia 1
For ongoing bone disease management, denosumab 120 mg every 4 weeks can be used, with treatment duration up to 2 years, and continuation beyond 2 years based on clinical judgment 1, 2, 3

Denosumab is specifically preferred over bisphosphonates in patients with renal disease because it requires no dose adjustment for renal impairment and can be safely administered to patients on hemodialysis, according to the National Comprehensive Cancer Network 2, 3, 1
Unlike zoledronic acid, denosumab does not require renal dose adjustment, and carries lower renal toxicity risk compared to bisphosphonates 1, 3

Mandatory calcium supplementation and vitamin D3 must be provided to prevent severe post-treatment hypocalcemia, with a recommended dose of 500-1,000 mg daily and 400-800 IU to 1,000-2,000 IU daily, respectively 1, 4
Correct any pre-existing hypocalcemia before administering denosumab, and optimize 25-hydroxyvitamin D levels before treatment initiation 1, 4
Measure serum calcium, phosphate, vitamin D, PTH, alkaline phosphatase, and creatinine clearance before treatment, and perform a mandatory baseline dental examination to reduce osteonecrosis of the jaw risk 2, 3, 1, 4

The incidence of hypocalcemia in ESRD patients receiving denosumab is approximately 42%, significantly higher than the 13% seen in patients with normal renal function, and regular calcium monitoring should be continued throughout treatment 1
Monitor PTH and alkaline phosphatase levels, as denosumab significantly reduces both markers, and assess for signs of ONJ throughout treatment, with a risk of 1-3% 2, 3, 1

Failure to provide adequate calcium and vitamin D prophylaxis is the most common cause of severe symptomatic hypocalcemia, and severe hypocalcemia may require hospitalization and prolonged IV calcium treatment 4
Do not abruptly discontinue denosumab without follow-up therapy, as this can lead to rebound bone resorption and paradoxical hypercalcemia 4

For acute hypercalcemia management, denosumab should be used alongside hydration, steroids, and/or calcitonin, according to the National Comprehensive Cancer Network 2, 3